Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Technical Development of Multi-Parametric Renocerebral MRI
Recruiting
The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and functional MRI methods along with a battery of cognitive tests.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
10/31/2024
Locations: Center for Magnetic Resonance Research, Minneapolis, Minnesota
Conditions: Aging
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Recruiting
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.
Gender:
ALL
Ages:
Between 14 years and 65 years
Trial Updated:
10/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
Recruiting
Researchers plan to study the natural history of ado-trastuzumab emtansine (T-DM1)-induced neuropathy both in patients without any history of neuropathy or previous neurotoxic agent use and in patients who have such a history.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Essentia Health Baxter Clinic, Baxter, Minnesota
Conditions: Breast Neoplasm
An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II
Recruiting
The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).
Gender:
ALL
Ages:
Between 6 months and 75 years
Trial Updated:
10/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Leukocyte Adhesion Deficiency
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II
Recruiting
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
Gender:
ALL
Ages:
Between 6 months and 75 years
Trial Updated:
10/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Leukocyte Adhesion Deficiency
Evaluate the Safety and Clinical Activity of HH2853
Recruiting
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Advanced Solid Tumor, FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma
Brain Vascular and Neural Function Linked to Balance Across the Adult Lifespan
Recruiting
This is a single-arm, two-visit, non-randomized, cross sectional study identified as an intervention due to the use of a single bout of aerobic exercise to assess cerebrovascular function under the NIH rules. This study is not masked and its primary purpose is to develop a basic science understanding of the relationship between cerebrovascular health and balance control with aging. This study will involve 102 individuals classified as younger adults, middle-aged adults, and older adults who are... Read More
Gender:
ALL
Ages:
Between 21 years and 95 years
Trial Updated:
10/29/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Neurotypical, Cognitively Normal
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
Recruiting
HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There is only one currently FDA-approved treatment,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Hidradenitis Suppurativa
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
Recruiting
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Prostate Cancer
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
Recruiting
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/28/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Semantic Dementia
Treatment of ARDS With Instilled T3
Recruiting
It is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation index (OSI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: M Health Fairview Southdale Hospital, Edina, Minnesota
Conditions: ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation